Hepion CRV431 reduces fibrosis in new model of NASH

Hepion Pharmaceuticals

Hepion Pharmaceuticals (NASDAQ:HEPA) reported preclinical findings where CRV431, a novel cyclophilin inhibitor, significantly decreased the extent of liver fibrosis in a Western diet (WD) animal model of NASH. 

The WD model uses a diet high in fat, fructose and cholesterol in combination with carbon tetrachloride (CCl4) to cause significant fibrosis and hepatocellular carcinoma in mice. 

The WD and CCl4-treated mice received either 50mg/kg/day of CRV431, 10mg/kg/day of obeticholic acid (OCA), or vehicle control, orally. CRV431 reduced liver fibrosis by 82%, whereas OCA reduced fibrosis by 49%. CRV431 also reduced WD-associated weight gain by 83%.

“CRV431 has potently and consistently reduced liver fibrosis in every experimental model in which CRV431 has been examined,” CEO Dr. Robert Foster said in a statement.

“A total of seven studies spanning four experimental models and three independent testing sites have now shown CRV431 to decrease liver fibrosis arising from a variety of dietary, chemical, and biochemical insults. We plan to continue with many additional studies conducted in parallel with our clinical programs to develop a thorough understanding of this important mode of action in liver disease,” he added.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.